It’s taken 30 years and more than $565 million to make it happen: the first-ever malaria vaccine. The innoculation, called Mosquirix, is the first of its kind to fight a parasite and has the potential to transform the lives of millions of people living in malaria-stricken areas. An estimated half million people die from the disease every year, the majority children. Such deaths have fallen by 47% since 2000 thanks to better prevention methods, but many have been waiting a long time for a vaccine that could protect children better and earlier.
{iframe}http://fortune.com/2015/12/21/gsk-malaria-vaccine/{/iframe}